Cardiology panels
From evidence to practice: Narrowing the gap
Dr Keith Fox talks to Drs Gregg Stone and Robert Harrington about why it takes so long for new evidence-based therapies to be adopted in clinical practice, the importance of national registries, and what can be done to make treatment guidelines more useful.
Genetic beta-blockade
What are the implications of an exciting discovery of intrinsic genetic beta-blockade common to 40% of people of African ancestry?

Dr Eric Topol invites you to share your opinions.

Click here to view the video blog and join the discussion.

HeartWire clips
On moving to industry: Interview with Dr Terry Ferguson
In conversation with heartwire news and features editor Larry Husten, Dr Terry Ferguson muses on changes to daily life, decision making processes, and patient care from a different perspective resulting from his new position in industry.
The Cardiology Show
Surrogate end points on trial: ENHANCE and other controversies
Part 2 is now live!
Nine of the world's top cardiologists gathered in Chicago to take on the issues raised by data released at the American College of Cardiology Scientific Sessions.

Dr Valentin Fuster moderates this frank and sometimes heated discussion on the results of ENHANCE, STRADIVARIUS, ONTARGET, and PERISCOPE, and the questions they raise about the responsibility of industry and the relevance of surrogate end points.
Forum
Smoking ban?
Read about our forum moderator's heroic and sometimes comic efforts to get a smoking ban passed by her city council in tobacco country.
Thumbs up, thumbs down
Controversies: ENHANCE and ACCORD
Clinical trials are under attack and in the headlines. What is the proper role of the investigators? What are the responsibilities of industry? Join Drs Eric J Topol and Robert M Califf in a discussion of the many issues surrounding ENHANCE and ACCORD.
Question
Do you think the ACC and SCAI should continue to combine their annual meetings in future years?
(See:Arranged marriage: Funding and "cultural differences" may dictate whether SCAI-ACC/i2 stay hitched)
No
Yes
Vote








ACS  >  High-risk ACS
An update from the American College of Cardiology 2008 Scientific Sessions/i2 Summit-SCAI Annual Meeting
Apr 14, 2008 10:13 EDT / Antiplatelet therapy involves a balance between the prevention of thrombosis and bleeding. The AHA 2007 Scientific Sessions program included the long-awaited results from TRITON and presentations on areas of uncertainty, including cost-effectiveness, loading dose, duration of therapy and resistance.
Optimizing outcomes in STEMI patients
Apr 10, 2008 10:00 EDT / The volume of recently released - and sometimes conflicting - clinical trial data surrounding the treatment of patients with ACS has led to confusion as to what is the best therapeutic option for a given patient. Because of the varying results from these trials, clinicians currently struggle with what constitutes optimum antithrombin/antiplatelet strategy for patients with ACS. Join Dr Eric Bates and panelists Drs Peter Berger and Gregg Stone as they contextualize these data and discuss their applicability to clinical practice.
Steering Committee Members
Mar 3, 2008 16:00 EST / The CME programs of the High-Risk ACS Topic are under the medical direction of Drs Eric Bates, Christian Hamm, Gabriel Steg and Paul Teirstein.
Optimizing management of UA/NSTEMI: What do the new guidelines tell us?
Dec 10, 2007 11:00 EST / Join Drs Ferguson, Bhatt, and Stone as they discuss the new ACC/AHA guidelines for the management of UA/NSTEMI; from the choice of an initial invasive or conservative strategy to the myriad pharmacologic options, what's a cardiologist to do?
Emerging data on pharmacological strategies in patients with ST-elevated myocardial infarction (STEMI)
Nov 1, 2007 10:00 EDT / Pharmacologic treatment in ACS involves a careful balance of safety and efficacy since bleeding has emerged as a major predictor of adverse outcomes, including mortality. Hear Dr Gregg Stone present the interesting results of the HORIZONS AMI trial, which pitches bivalirudin against heparin+glycoprotein IIb/IIIa in STEMI patents undergoing primary PCI. Then listen to Drs William Knopf and Michael Lincoff give their response to the findings.


CME provider: Medscape.
The High-Risk ACS topic is supported by an educational grant from The Medicines Company.
More on the High-Risk ACS topic